Neutropenia
Welcome,         Profile    Billing    Logout  
 405 Companies   276 Products   276 Products   144 Mechanisms of Action   546 Trials   44510 News 


12345678910111213...621622»
  • ||||||||||  Journal:  Cryoablation of bone, soft tissue, and nerve in the setting of uninterrupted systemic cancer therapies. (Pubmed Central) -  Apr 9, 2025   
    Future studies should explore the factors influencing hematopoietic growth factor sensitivity in AML subpopulations to guide therapeutic decisions. Wound healing abnormalities were not observed when performing percutaneous cryoablation with uninterrupted systemic therapies in this study, even in treatment zones that had received radiotherapy and embolization.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer (clinicaltrials.gov) -  Apr 9, 2025   
    P=N/A,  N=93, Completed, 
    The Supplementary Material includes letters of support from 124 non-US clozapine experts from 44 countries/regions who support Parts I and II. Recruiting --> Completed | N=220 --> 93 | Trial completion date: Sep 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Jan 2025
  • ||||||||||  T-1101 / Taivex Therapeutics Corporation
    Trial completion date, Trial primary completion date:  Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors (clinicaltrials.gov) -  Apr 8, 2025   
    P1,  N=24, Active, not recruiting, 
    Recruiting --> Completed | N=220 --> 93 | Trial completion date: Sep 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Jan 2025 Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Journal:  Comorbidities in people living with HIV/AIDS and their impact on outpatient dental care. (Pubmed Central) -  Apr 8, 2025   
    In summary, psychiatric disorders and severe hematological alterations, such as anemia and neutropenia, are significant comorbidities that may limit dental treatment of HIV-positive patients. These findings underscore the need for integrated medical and dental care to address the complex health needs of PLWHIV.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, enitociclib (VIP152) / Vincerx
    Enrollment change, Trial completion date:  Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) -  Apr 8, 2025   
    P1/2,  N=8, Active, not recruiting, 
    These findings underscore the need for integrated medical and dental care to address the complex health needs of PLWHIV. N=130 --> 8 | Trial completion date: Jul 2029 --> Jun 2025
  • ||||||||||  Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date:  Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (clinicaltrials.gov) -  Apr 7, 2025   
    P2,  N=36, Active, not recruiting, 
    The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC. Trial completion date: Dec 2029 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2027
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen
    Trial completion date, Trial primary completion date:  OLYMP-1: Obinutuzumab in Marginal Zone Lymphoma (clinicaltrials.gov) -  Apr 7, 2025   
    P2,  N=56, Active, not recruiting, 
    Trial completion date: Dec 2029 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2027 Trial completion date: Nov 2028 --> Jan 2027 | Trial primary completion date: Jun 2024 --> Jan 2027
  • ||||||||||  Journal:  Diagnosis of Duffy Null-Associated Neutropenia During Chemotherapy. (Pubmed Central) -  Apr 5, 2025   
    The review highlights the need for cancer care providers to anticipate treatment-related side effects and mitigate them ahead of time, providing necessary prophylactic measures and treatment support. No abstract available
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  CLL cell-derived exosomes alter the immune and hematopoietic systems. (Pubmed Central) -  Apr 5, 2025   
    CLL cell-derived exosomes inhibited hematopoietic progenitor proliferation, hindering the supportive effect of monocyte-derived fibrocytes. Together, our findings suggest that CLL cell-derived exosomes disrupt the immune and hematopoietic systems and contribute to disease progression in patients with CLL.
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    P1 data, Journal:  A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) -  Apr 3, 2025   
    P1
    Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel...Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
  • ||||||||||  Journal:  Risk of Superficial Fungal Infections in WHIM Syndrome. (Pubmed Central) -  Apr 3, 2025   
    P
    Further studies with larger cohorts are necessary to confirm these findings. These findings suggest that frequent or prolonged superficial fungal infections may be a useful clinical sign to prompt consideration of a WHIM syndrome diagnosis, especially in patients with numerous cutaneous warts or other history to suggest immunodeficiency.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Journal:  Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. (Pubmed Central) -  Apr 3, 2025   
    The ADC comprises native polatuzumab as the targeting antibody and a linker-payload consisting of a RKAA-peptide linker and MMAE...In summary, the data show that our novel site-specific bioconjugation technology enabled the generation of an anti-CD79b-RKAA-MMAE ADC with highly favorable biophysical properties and a greatly improved therapeutic index by a factor of 4 to 6 compared with PV. The ADC may therefore represent a safe and efficacious alternative for patients with diffuse large B-cell lymphoma.